Printer Friendly

Phase Forward to Present at World Drug Safety Congress Europe.

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in the 3rd annual World Drug Safety Congress Europe, to be held September 15-18 at the Bloomsbury Hotel in London, U.K.

On Wednesday, September 16, from 1:30-2:00 p.m. local time, Robert Weber, principal consultant of Phase Forward's Lincoln Safety Group, will participate in stream session 2 titled "Post Marketing Safety Strategy." Mr. Weber's presentation will review the prioritization, tracking and management of signals from multiple sources, such as spontaneous adverse event reports, clinical studies and observational studies. In addition, Mr. Weber will discuss the importance of processes and integrated tools to deliver improved safety monitoring and risk management.

Phase Forward will also showcase its safety solutions, the Empirica[TM] Suite, which comprises the following products: Empirica Trace, Empirica Gateway, Empirica Signal and Empirica Study.

Members of the media interested in speaking with Mr. Weber and/or Phase Forward at the event should visit Phase Forward booth #7 or contact Maria Sumner at +44 1628 640743 or

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 9, 2009
Previous Article:hhgregg Announces Grand Opening of New Store in Evansville, IN.
Next Article:Fitch Rates Agilent Technologies' Proposed $500MM Senior Unsecured Notes 'BBB'.

Related Articles
Cerus Initiates Phase I Clinical Trial for INTERCEPT Blood System for Red Blood Cells.
Phase Forward to Host Sixth Annual European Users Conference.
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R).
Phase Forward to Participate in World Drug Safety Congress Europe.
Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting.
Phase Forward to Share Expertise at DIA Clinical Forum and CReaTE 08.
U.S. Department of Defense Chooses Phase Forward to Support FDA-Sponsored Drug Safety Initiative.
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial.
Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting.
Teva Comments on Positive Results of Phase III Trial in MediWound's Debrase[R].

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters